甲状腺癌组织中galectin-3、CK19的表达及应用价值Studing the value of galectin-3, CK19 expression in the thyroid cancer
肖红,段绍斌,张建勇,范健
摘要(Abstract)：
目的:探讨半乳糖凝集素-3(galectin-3)和细胞角蛋白19(CK19)在甲状腺良、恶性病变组织中的表达及应用价值。方法:采用免疫组织化学方法(SP法)检测68例甲状腺良、恶性病变组织中galectin-3、CK19的表达情况,比较有、无淋巴结转移甲状腺癌组织中galectin-3、CK19的表达差异,并计算检测的灵敏度和特异度。结果:30例甲状腺癌组织中galectin-3、CK19阳性表达率分别为90.0%、96.7%,38例甲状腺良性病变组织中阳性表达率分别为15.8%、7.9%,良、恶性病变组织阳性表达率差异有统计学意义(P<0.05)。淋巴结转移甲状腺癌组织中galectin-3的阳性表达率为100.0%,无淋巴结转移甲状腺癌组织的阳性表达率为62.5%,差异有统计学意义(P<0.05)。淋巴结转移甲状腺癌组织CK19的阳性表达率为100.0%,无淋巴结转移甲状腺癌组织的阳性表达率为87.5%,差异无统计学意义(P>0.05)。galectin-3联合CK19检测甲状腺良、恶性病变的灵敏度、特异度分别为90.0%、92.1%,单独检测galectin-3的灵敏度、特异度分别为90.0%、84.2%、96.7%、92.1%。结论:galectin-3的表达与颈淋巴结转移有关,对预测甲状腺癌的发展及淋巴结转移有参考价值。galectin-3和CK19在甲状腺良、恶性病变组织中的表达基本平行,二者联合检测有助于鉴别甲状腺良、恶性病变。
关键词(KeyWords)： 甲状腺;良、恶性病变;细胞角蛋白19;半乳糖凝集素-3;免疫组织化学
基金项目(Foundation):
作者(Author): 肖红,段绍斌,张建勇,范健
参考文献(References)：
- [1] Cady B.Presidential address:beyond risk groups-a newlook at differentiated thyroid cancer[J].Surgery,1998,124:947-957.
- [2] Noguchi S,Murakami N,Yamashita H,et al.Papillary thy-roid carcinoma:modified radical neck dissectioni mproves prog-nosis[J].Arch Surg,1998,133:276-280.
- [3] Schelfhout LJ,Crentzbery CL,Hamming JF,et al.Multivari-ate analysis of survival in differentiated thyroid cancer,The prognostic significance of the age factor[J].Eur J Cancer Clin Oncol,1998,24(2):331-337.
- [4] Xu XC,el-Naggar AK,Lotan R,et al.Differential expression of galectin-1and galection-3in thyroid tumors.Potential diag-nostic i mplications[J].AmJ Pathol,1995,147(3):815-822.
- [5] Coli A,Bigotti G,Zucchetti F,et al.galectin-3,a marker of welldifferentiated thyroid cancirnoma,is expressed in thyroid nodules with cytological atypia[J].Histopathology,2002,40:80-87.
- [6] Niedobitek C,Niedobitek F,Lindenberg G,et al.Expression of galectin-3in thyroid gland and follicular cell tumors of the thyroid.Acritical study of its possible rolein p reoperative dif-ferential diagnosis[J].Pathology,2001,22:205-213.
- [7] Kovacs RB,Foldes J,Winkler G,et al.The investigation of galection-3in diseases of the thyroid gland[J].Eur J Endocri-nol,2003,149(5):449-453.